Abstract
Twenty medications are associated with drug-induced organizing pneumonia; however, thalidomide is not listed as a potential causative agent. Thalidomide (Thalomid, Celgene Corp., Summit, NJ), an angiogenesis inhibitor and immunomodulator that reduces tumor necrosis factor-alpha, is used for the treatment of multiple myeloma. We report a case of organizing pneumonia in a 58-year-old male with multiple myeloma treated with dexamethasone and thalidomide.
MeSH terms
-
Adult
-
Angiogenesis Inhibitors / adverse effects*
-
Angiogenesis Inhibitors / therapeutic use
-
Cryptogenic Organizing Pneumonia / chemically induced*
-
Cryptogenic Organizing Pneumonia / diagnostic imaging
-
Cryptogenic Organizing Pneumonia / pathology
-
Humans
-
Immunosuppressive Agents / adverse effects*
-
Immunosuppressive Agents / therapeutic use
-
Male
-
Multiple Myeloma / drug therapy
-
Thalidomide / adverse effects*
-
Thalidomide / therapeutic use
-
Tomography, X-Ray Computed
Substances
-
Angiogenesis Inhibitors
-
Immunosuppressive Agents
-
Thalidomide